JOP20200109A1 - مستحضر قابل للحقن - Google Patents

مستحضر قابل للحقن

Info

Publication number
JOP20200109A1
JOP20200109A1 JOP/2020/0109A JOP20200109A JOP20200109A1 JO P20200109 A1 JOP20200109 A1 JO P20200109A1 JO P20200109 A JOP20200109 A JO P20200109A JO P20200109 A1 JOP20200109 A1 JO P20200109A1
Authority
JO
Jordan
Prior art keywords
injectable preparation
composition
present
viscosity
dispersion medium
Prior art date
Application number
JOP/2020/0109A
Other languages
Arabic (ar)
English (en)
Inventor
Hoshika Yusuke
Kaneko Daiki
Matsuda Takakuni
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200109(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of JOP20200109A1 publication Critical patent/JOP20200109A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOP/2020/0109A 2012-04-23 2012-04-23 مستحضر قابل للحقن JOP20200109A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636938P 2012-04-23 2012-04-23
US201361792089P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JOP20200109A1 true JOP20200109A1 (ar) 2017-06-16

Family

ID=48614096

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0109A JOP20200109A1 (ar) 2012-04-23 2012-04-23 مستحضر قابل للحقن
JOP/2013/0116A JO3632B1 (ar) 2012-04-23 2013-04-23 مستحضر قابل للحقن

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2013/0116A JO3632B1 (ar) 2012-04-23 2013-04-23 مستحضر قابل للحقن

Country Status (31)

Country Link
US (9) US20150093442A1 (OSRAM)
EP (2) EP2841054B2 (OSRAM)
JP (7) JP6234996B2 (OSRAM)
KR (4) KR20240068788A (OSRAM)
CN (3) CN104470499B (OSRAM)
AR (1) AR090776A1 (OSRAM)
AU (6) AU2013253374B2 (OSRAM)
BR (1) BR112014026307B1 (OSRAM)
CA (2) CA2869889C (OSRAM)
CO (1) CO7151500A2 (OSRAM)
CY (1) CY1122252T1 (OSRAM)
DK (1) DK2841054T4 (OSRAM)
EA (1) EA026619B1 (OSRAM)
ES (1) ES2743706T5 (OSRAM)
HR (1) HRP20191366T4 (OSRAM)
HU (1) HUE045979T2 (OSRAM)
IL (1) IL235299B (OSRAM)
JO (2) JOP20200109A1 (OSRAM)
LT (1) LT2841054T (OSRAM)
MX (2) MX387891B (OSRAM)
MY (3) MY198007A (OSRAM)
NZ (1) NZ630335A (OSRAM)
PH (2) PH12014502379B1 (OSRAM)
PL (1) PL2841054T5 (OSRAM)
PT (1) PT2841054T (OSRAM)
SG (3) SG10201913425VA (OSRAM)
SI (1) SI2841054T2 (OSRAM)
TW (6) TW202313036A (OSRAM)
UA (1) UA115444C2 (OSRAM)
WO (1) WO2013162048A1 (OSRAM)
ZA (1) ZA201407335B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Ｓｉｃｈｕａｎ Ｙｉｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｍｐａｎｙ ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用
US10987303B2 (en) 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
WO2020089942A2 (en) * 2018-11-02 2020-05-07 Amaterasu Lifesciences Llp A liquid injectable composition
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
CA3163321C (en) * 2020-04-01 2023-12-19 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11910794B2 (en) * 2021-03-08 2024-02-27 Monsanto Technology Llc Solutions and methods for long-term pollen storage
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法
JP7760615B2 (ja) * 2022-06-16 2025-10-27 ウィズダム・ファーマスーティカル・カンパニー・リミテッド 薬物組成物及びブレクスピプラゾール口腔内溶解フィルム
CN115969785A (zh) * 2022-12-30 2023-04-18 辰欣药业股份有限公司 一种阿立哌唑注射剂及其制备方法
WO2024194955A1 (en) * 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
WO2024225441A1 (en) 2023-04-26 2024-10-31 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole
WO2025051282A1 (zh) * 2023-09-08 2025-03-13 广州玻思韬控释药业有限公司 注射用凝胶
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864100A (en) * 1957-04-09 1961-03-29 Pfizer & Co C Therapeutic pencillin compositions and the preparation thereof
JPS5913714A (ja) 1982-07-13 1984-01-24 Taito Pfizer Kk 外用消炎鎮痛剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
JP2003171264A (ja) * 2001-12-07 2003-06-17 Taiyo Yakuhin Kogyo Kk マイクロカプセル及びその製造方法
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
PL212428B1 (pl) * 2002-08-20 2012-09-28 Bristol Myers Squibb Co Kompleks aripiprazolu, preparat farmaceutyczny zawierajacy ten kompleks i jego zastosowanie
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BRPI0305500B1 (pt) 2003-01-09 2018-01-23 Otsuka Pharmaceutical Co., Ltd. Processo para preparar aripiprazol
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
CA2523484A1 (en) * 2003-05-02 2004-11-11 Rimon Therapeutics Ltd. Thermally reversible implant
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
EP1677762A1 (en) 2003-10-27 2006-07-12 Dow Corning Corporation A controlled-release composition for topical application and a method of delivering an active agent to a substrate
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
JP2006219380A (ja) * 2005-02-08 2006-08-24 Minofuaagen Seiyaku:Kk グリチルリチン皮下注射製剤
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
ES2437581T3 (es) 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CL2007002851A1 (es) * 2006-10-05 2008-01-18 M S Panacea Biotec Ltd Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
US20100151459A1 (en) 2007-01-26 2010-06-17 Jun Soo Kwon Marker for detecting the proposed efficacy of treatment
CA2691597C (en) 2007-06-25 2016-04-05 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
NO2170279T3 (OSRAM) 2007-07-31 2018-05-26
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc Stabilized therapeutic compositions and formulations
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2009286740A (ja) 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
TR200809200A1 (tr) 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
RU2555760C2 (ru) 2009-09-11 2015-07-10 Оцука Фармасьютикал Ко., Лтд. Терапевтический агент против хронической боли
SG184879A1 (en) * 2010-08-24 2012-11-29 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
JP2012121850A (ja) 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
WO2012102216A1 (en) 2011-01-24 2012-08-02 Otsuka Pharmaceutical Co., Ltd. Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
JOP20120083B1 (ar) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
GB2505860B (en) 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
JP5832558B2 (ja) 2011-07-28 2015-12-16 大塚製薬株式会社 ベンゾ［ｂ］チオフェン化合物の製造方法
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI679977B (zh) 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JP2013139441A (ja) 2011-12-28 2013-07-18 Otsuka Pharmaceut Co Ltd マイクロスフェア
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
KR20150003861A (ko) 2015-01-09
AU2020204200B2 (en) 2022-06-30
AU2017228608C1 (en) 2019-02-21
US20190336607A1 (en) 2019-11-07
UA115444C2 (uk) 2017-11-10
TW201900174A (zh) 2019-01-01
AU2017228608B2 (en) 2018-10-18
SI2841054T2 (sl) 2022-05-31
AU2013253374B2 (en) 2017-06-15
JP7612758B2 (ja) 2025-01-14
CN104470499A (zh) 2015-03-25
PL2841054T5 (pl) 2022-07-18
NZ630335A (en) 2016-07-29
MY210484A (en) 2025-09-24
KR102138852B1 (ko) 2020-07-28
JP2021008512A (ja) 2021-01-28
TW202313036A (zh) 2023-04-01
MX2014012811A (es) 2015-05-07
JO3632B1 (ar) 2020-08-27
HRP20191366T1 (hr) 2019-12-27
JP2025041805A (ja) 2025-03-26
HK1206988A1 (en) 2016-01-22
US20180055941A1 (en) 2018-03-01
HRP20191366T4 (hr) 2022-08-19
IL235299B (en) 2019-12-31
IL235299A0 (en) 2014-12-31
EP2841054A1 (en) 2015-03-04
CY1122252T1 (el) 2020-11-25
JP2015514751A (ja) 2015-05-21
JP2022050619A (ja) 2022-03-30
WO2013162048A1 (en) 2013-10-31
AU2020204200A1 (en) 2020-07-16
AU2022241491B2 (en) 2024-10-24
CN114344259A (zh) 2022-04-15
TWI637752B (zh) 2018-10-11
BR112014026307B1 (pt) 2022-10-11
EA201491685A1 (ru) 2015-04-30
CA3120297A1 (en) 2013-10-31
US20220096638A1 (en) 2022-03-31
US10517951B2 (en) 2019-12-31
PT2841054T (pt) 2019-09-09
KR102498075B1 (ko) 2023-02-10
US11097007B2 (en) 2021-08-24
CO7151500A2 (es) 2014-12-29
TWI713826B (zh) 2020-12-21
AR090776A1 (es) 2014-12-03
EP2841054B1 (en) 2019-06-26
AU2022241491A1 (en) 2022-10-20
SG10201913425VA (en) 2020-03-30
JP2019070028A (ja) 2019-05-09
TW202126303A (zh) 2021-07-16
HK1257028A1 (zh) 2019-10-11
DK2841054T4 (da) 2022-06-13
US20190099494A1 (en) 2019-04-04
BR112014026307A2 (pt) 2017-06-27
EP2841054B2 (en) 2022-04-06
CN108186556B (zh) 2022-06-10
MX359241B (es) 2018-09-20
JP2018048179A (ja) 2018-03-29
AU2017228608A1 (en) 2017-10-05
CA2869889C (en) 2021-07-20
US20250121065A1 (en) 2025-04-17
DK2841054T3 (da) 2019-09-09
TW201350136A (zh) 2013-12-16
CN114344259B (zh) 2024-02-13
AU2019200060A1 (en) 2019-01-31
JP2023113806A (ja) 2023-08-16
MX387891B (es) 2025-03-19
CA2869889A1 (en) 2013-10-31
US11638757B2 (en) 2023-05-02
JP7293412B2 (ja) 2023-06-19
JP6470378B2 (ja) 2019-02-13
ES2743706T5 (es) 2022-05-25
JP6234996B2 (ja) 2017-11-22
HUE045979T2 (hu) 2020-01-28
KR20200064173A (ko) 2020-06-05
AU2013253374A1 (en) 2014-10-23
US12016927B2 (en) 2024-06-25
US20200179517A1 (en) 2020-06-11
TW202535396A (zh) 2025-09-16
TW202425992A (zh) 2024-07-01
CN104470499B (zh) 2018-03-16
PH12014502379A1 (en) 2015-01-12
AU2025200229A1 (en) 2025-01-30
SG10201608753UA (en) 2016-12-29
US20230390399A1 (en) 2023-12-07
CN108186556A (zh) 2018-06-22
MY198007A (en) 2023-07-25
PH12014502379B1 (en) 2015-01-12
ES2743706T3 (es) 2020-02-20
EP3539534A1 (en) 2019-09-18
SI2841054T1 (sl) 2019-09-30
KR20240068788A (ko) 2024-05-17
LT2841054T (lt) 2019-09-10
US20150093442A1 (en) 2015-04-02
PL2841054T3 (pl) 2019-10-31
PH12019500498A1 (en) 2020-03-02
SG11201406451SA (en) 2014-11-27
US20210085794A1 (en) 2021-03-25
EA026619B1 (ru) 2017-04-28
KR20210116702A (ko) 2021-09-27
ZA201407335B (en) 2019-06-26
MY178573A (en) 2020-10-16

Similar Documents

Publication Publication Date Title
PH12019500498A1 (en) Injectable preparation
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2013002932A (es) Formulaciones agricolas liquidas de estabilidad mejorada.
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
MX355831B (es) NOVEDOSOS HIDRATOS CRISTALINOS DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3 -[5-(4-FLUORO-FENIL)-2-TIENIL-METIL]-BENCENO.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
TW201613620A (en) Jelly-like medicinal composition of potassium iodide
MX2015015075A (es) Dispositivo de administracion de farmaco y metodo de ensamblaje del mismo.
PH12015501313A1 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
PH12013500727A1 (en) Sustained-release pharmaceutical composition
IN2012CH05549A (OSRAM)
MX2021015921A (es) Preparacion inyectable.
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
EA027609B9 (ru) Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа
TH157429A (th) สารเตรียมชนิดฉีดได้
BR112015022000A8 (pt) preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação
IN2013CH01615A (OSRAM)